HAEM5:Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes: Difference between revisions
| [pending revision] | [pending revision] |
| Line 97: | Line 97: | ||
|inv(2)(p23q13) / t(2;2)(p23;q13)<ref>{{Cite journal|last=Röttgers|first=S.|last2=Gombert|first2=M.|last3=Teigler-Schlegel|first3=A.|last4=Busch|first4=K.|last5=Gamerdinger|first5=U.|last6=Slany|first6=R.|last7=Harbott|first7=J.|last8=Borkhardt|first8=A.|date=2010-06|title=ALK fusion genes in children with atypical myeloproliferative leukemia|url=https://pubmed.ncbi.nlm.nih.gov/20428197|journal=Leukemia|volume=24|issue=6|pages=1197–1200|doi=10.1038/leu.2010.18|issn=1476-5551|pmid=20428197}}</ref> <ref>{{Cite journal|last=Lim|first=Ji-Hun|last2=Jang|first2=Seongsoo|last3=Park|first3=Chan-Jeoung|last4=Cho|first4=Young-Uk|last5=Lee|first5=Je-Hwan|last6=Lee|first6=Kyoo-Hyung|last7=Lee|first7=Jin-Ok|last8=Shin|first8=Jong-Yeon|last9=Kim|first9=Jong-Il|date=2014|title=RANBP2-ALK fusion combined with monosomy 7 in acute myelomonocytic leukemia|url=https://pubmed.ncbi.nlm.nih.gov/24613277|journal=Cancer Genetics|volume=207|issue=1-2|pages=40–45|doi=10.1016/j.cancergen.2013.12.003|issn=2210-7762|pmid=24613277}}</ref> | |inv(2)(p23q13) / t(2;2)(p23;q13)<ref>{{Cite journal|last=Röttgers|first=S.|last2=Gombert|first2=M.|last3=Teigler-Schlegel|first3=A.|last4=Busch|first4=K.|last5=Gamerdinger|first5=U.|last6=Slany|first6=R.|last7=Harbott|first7=J.|last8=Borkhardt|first8=A.|date=2010-06|title=ALK fusion genes in children with atypical myeloproliferative leukemia|url=https://pubmed.ncbi.nlm.nih.gov/20428197|journal=Leukemia|volume=24|issue=6|pages=1197–1200|doi=10.1038/leu.2010.18|issn=1476-5551|pmid=20428197}}</ref> <ref>{{Cite journal|last=Lim|first=Ji-Hun|last2=Jang|first2=Seongsoo|last3=Park|first3=Chan-Jeoung|last4=Cho|first4=Young-Uk|last5=Lee|first5=Je-Hwan|last6=Lee|first6=Kyoo-Hyung|last7=Lee|first7=Jin-Ok|last8=Shin|first8=Jong-Yeon|last9=Kim|first9=Jong-Il|date=2014|title=RANBP2-ALK fusion combined with monosomy 7 in acute myelomonocytic leukemia|url=https://pubmed.ncbi.nlm.nih.gov/24613277|journal=Cancer Genetics|volume=207|issue=1-2|pages=40–45|doi=10.1016/j.cancergen.2013.12.003|issn=2210-7762|pmid=24613277}}</ref> | ||
|Rare < 5% | |Rare < 5% | ||
| | |D, P, T | ||
|Yes (WHO) | |Yes (WHO) | ||
|Resistant to intensive chemotherapy and allogeneic SCT. Poor clinical outcome.<ref>{{Cite journal|last=Lim|first=Ji-Hun|last2=Jang|first2=Seongsoo|last3=Park|first3=Chan-Jeoung|last4=Cho|first4=Young-Uk|last5=Lee|first5=Je-Hwan|last6=Lee|first6=Kyoo-Hyung|last7=Lee|first7=Jin-Ok|last8=Shin|first8=Jong-Yeon|last9=Kim|first9=Jong-Il|date=2014|title=RANBP2-ALK fusion combined with monosomy 7 in acute myelomonocytic leukemia|url=https://pubmed.ncbi.nlm.nih.gov/24613277|journal=Cancer Genetics|volume=207|issue=1-2|pages=40–45|doi=10.1016/j.cancergen.2013.12.003|issn=2210-7762|pmid=24613277}}</ref> Prognosis is not well defined due to the small number of cases. | |Resistant to intensive chemotherapy and allogeneic SCT. Poor clinical outcome.<ref>{{Cite journal|last=Lim|first=Ji-Hun|last2=Jang|first2=Seongsoo|last3=Park|first3=Chan-Jeoung|last4=Cho|first4=Young-Uk|last5=Lee|first5=Je-Hwan|last6=Lee|first6=Kyoo-Hyung|last7=Lee|first7=Jin-Ok|last8=Shin|first8=Jong-Yeon|last9=Kim|first9=Jong-Il|date=2014|title=RANBP2-ALK fusion combined with monosomy 7 in acute myelomonocytic leukemia|url=https://pubmed.ncbi.nlm.nih.gov/24613277|journal=Cancer Genetics|volume=207|issue=1-2|pages=40–45|doi=10.1016/j.cancergen.2013.12.003|issn=2210-7762|pmid=24613277}}</ref> Prognosis is not well defined due to the small number of cases. | ||
| Line 105: | Line 105: | ||
''RET'' | ''RET'' | ||
|''BCR::RET''<ref>{{Cite journal|last=Ballerini|first=P.|last2=Struski|first2=S.|last3=Cresson|first3=C.|last4=Prade|first4=N.|last5=Toujani|first5=S.|last6=Deswarte|first6=C.|last7=Dobbelstein|first7=S.|last8=Petit|first8=A.|last9=Lapillonne|first9=H.|date=2012-11|title=RET fusion genes are associated with chronic myelomonocytic leukemia and enhance monocytic differentiation|url=https://pubmed.ncbi.nlm.nih.gov/22513837|journal=Leukemia|volume=26|issue=11|pages=2384–2389|doi=10.1038/leu.2012.109|issn=1476-5551|pmid=22513837}}</ref> | |''BCR::RET''<ref>{{Cite journal|last=Ballerini|first=P.|last2=Struski|first2=S.|last3=Cresson|first3=C.|last4=Prade|first4=N.|last5=Toujani|first5=S.|last6=Deswarte|first6=C.|last7=Dobbelstein|first7=S.|last8=Petit|first8=A.|last9=Lapillonne|first9=H.|date=2012-11|title=RET fusion genes are associated with chronic myelomonocytic leukemia and enhance monocytic differentiation|url=https://pubmed.ncbi.nlm.nih.gov/22513837|journal=Leukemia|volume=26|issue=11|pages=2384–2389|doi=10.1038/leu.2012.109|issn=1476-5551|pmid=22513837}}</ref> | ||
| | |Fusion between ''BCR'' exon 4 with the ''RET'' exon 12 (5′ to 3′ orientation).<ref>{{Cite journal|last=Ballerini|first=P.|last2=Struski|first2=S.|last3=Cresson|first3=C.|last4=Prade|first4=N.|last5=Toujani|first5=S.|last6=Deswarte|first6=C.|last7=Dobbelstein|first7=S.|last8=Petit|first8=A.|last9=Lapillonne|first9=H.|date=2012-11|title=RET fusion genes are associated with chronic myelomonocytic leukemia and enhance monocytic differentiation|url=https://pubmed.ncbi.nlm.nih.gov/22513837|journal=Leukemia|volume=26|issue=11|pages=2384–2389|doi=10.1038/leu.2012.109|issn=1476-5551|pmid=22513837}}</ref> Aberrant expression of the kinase domain. | ||
|t(10;22)(q11;q11)<ref>{{Cite journal|last=Ballerini|first=P.|last2=Struski|first2=S.|last3=Cresson|first3=C.|last4=Prade|first4=N.|last5=Toujani|first5=S.|last6=Deswarte|first6=C.|last7=Dobbelstein|first7=S.|last8=Petit|first8=A.|last9=Lapillonne|first9=H.|date=2012-11|title=RET fusion genes are associated with chronic myelomonocytic leukemia and enhance monocytic differentiation|url=https://pubmed.ncbi.nlm.nih.gov/22513837|journal=Leukemia|volume=26|issue=11|pages=2384–2389|doi=10.1038/leu.2012.109|issn=1476-5551|pmid=22513837}}</ref> | |t(10;22)(q11;q11)<ref>{{Cite journal|last=Ballerini|first=P.|last2=Struski|first2=S.|last3=Cresson|first3=C.|last4=Prade|first4=N.|last5=Toujani|first5=S.|last6=Deswarte|first6=C.|last7=Dobbelstein|first7=S.|last8=Petit|first8=A.|last9=Lapillonne|first9=H.|date=2012-11|title=RET fusion genes are associated with chronic myelomonocytic leukemia and enhance monocytic differentiation|url=https://pubmed.ncbi.nlm.nih.gov/22513837|journal=Leukemia|volume=26|issue=11|pages=2384–2389|doi=10.1038/leu.2012.109|issn=1476-5551|pmid=22513837}}</ref> | ||
| | |Rare <5% | ||
| | |D, P, T | ||
| | |Yes (WHO) | ||
| | | | ||
Sensitive to Sorafenib, an inhibitor to tyrosine kinase activity. | Associated with chronic myelomonocytic leukemia and monocytic differentiation. Sensitive to Sorafenib, an inhibitor to tyrosine kinase activity.<ref>{{Cite journal|last=Ballerini|first=P.|last2=Struski|first2=S.|last3=Cresson|first3=C.|last4=Prade|first4=N.|last5=Toujani|first5=S.|last6=Deswarte|first6=C.|last7=Dobbelstein|first7=S.|last8=Petit|first8=A.|last9=Lapillonne|first9=H.|date=2012-11|title=RET fusion genes are associated with chronic myelomonocytic leukemia and enhance monocytic differentiation|url=https://pubmed.ncbi.nlm.nih.gov/22513837|journal=Leukemia|volume=26|issue=11|pages=2384–2389|doi=10.1038/leu.2012.109|issn=1476-5551|pmid=22513837}}</ref> The prognosis not well defined due to the limited number of cases. | ||
| Line 126: | Line 125: | ||
''RET'' | ''RET'' | ||
|''FGFR1OP::RET''<ref>{{Cite journal|last=Ballerini|first=P.|last2=Struski|first2=S.|last3=Cresson|first3=C.|last4=Prade|first4=N.|last5=Toujani|first5=S.|last6=Deswarte|first6=C.|last7=Dobbelstein|first7=S.|last8=Petit|first8=A.|last9=Lapillonne|first9=H.|date=2012-11|title=RET fusion genes are associated with chronic myelomonocytic leukemia and enhance monocytic differentiation|url=https://pubmed.ncbi.nlm.nih.gov/22513837|journal=Leukemia|volume=26|issue=11|pages=2384–2389|doi=10.1038/leu.2012.109|issn=1476-5551|pmid=22513837}}</ref> | |''FGFR1OP::RET''<ref>{{Cite journal|last=Ballerini|first=P.|last2=Struski|first2=S.|last3=Cresson|first3=C.|last4=Prade|first4=N.|last5=Toujani|first5=S.|last6=Deswarte|first6=C.|last7=Dobbelstein|first7=S.|last8=Petit|first8=A.|last9=Lapillonne|first9=H.|date=2012-11|title=RET fusion genes are associated with chronic myelomonocytic leukemia and enhance monocytic differentiation|url=https://pubmed.ncbi.nlm.nih.gov/22513837|journal=Leukemia|volume=26|issue=11|pages=2384–2389|doi=10.1038/leu.2012.109|issn=1476-5551|pmid=22513837}}</ref> | ||
|Fusion between ''FGFR1OP'' exon 12 with ''RET'' exon 12.<ref>{{Cite journal|last=Ballerini|first=P.|last2=Struski|first2=S.|last3=Cresson|first3=C.|last4=Prade|first4=N.|last5=Toujani|first5=S.|last6=Deswarte|first6=C.|last7=Dobbelstein|first7=S.|last8=Petit|first8=A.|last9=Lapillonne|first9=H.|date=2012-11|title=RET fusion genes are associated with chronic myelomonocytic leukemia and enhance monocytic differentiation|url=https://pubmed.ncbi.nlm.nih.gov/22513837|journal=Leukemia|volume=26|issue=11|pages=2384–2389|doi=10.1038/leu.2012.109|issn=1476-5551|pmid=22513837}}</ref> | |Fusion between ''FGFR1OP'' exon 12 with ''RET'' exon 12 (5′ to 3′ orientation).<ref>{{Cite journal|last=Ballerini|first=P.|last2=Struski|first2=S.|last3=Cresson|first3=C.|last4=Prade|first4=N.|last5=Toujani|first5=S.|last6=Deswarte|first6=C.|last7=Dobbelstein|first7=S.|last8=Petit|first8=A.|last9=Lapillonne|first9=H.|date=2012-11|title=RET fusion genes are associated with chronic myelomonocytic leukemia and enhance monocytic differentiation|url=https://pubmed.ncbi.nlm.nih.gov/22513837|journal=Leukemia|volume=26|issue=11|pages=2384–2389|doi=10.1038/leu.2012.109|issn=1476-5551|pmid=22513837}}</ref> Abnormal expression of the tyrosine kinase domain. | ||
|t(6;10)(q27;q11)<ref>{{Cite journal|last=Ballerini|first=P.|last2=Struski|first2=S.|last3=Cresson|first3=C.|last4=Prade|first4=N.|last5=Toujani|first5=S.|last6=Deswarte|first6=C.|last7=Dobbelstein|first7=S.|last8=Petit|first8=A.|last9=Lapillonne|first9=H.|date=2012-11|title=RET fusion genes are associated with chronic myelomonocytic leukemia and enhance monocytic differentiation|url=https://pubmed.ncbi.nlm.nih.gov/22513837|journal=Leukemia|volume=26|issue=11|pages=2384–2389|doi=10.1038/leu.2012.109|issn=1476-5551|pmid=22513837}}</ref> | |t(6;10)(q27;q11)<ref>{{Cite journal|last=Ballerini|first=P.|last2=Struski|first2=S.|last3=Cresson|first3=C.|last4=Prade|first4=N.|last5=Toujani|first5=S.|last6=Deswarte|first6=C.|last7=Dobbelstein|first7=S.|last8=Petit|first8=A.|last9=Lapillonne|first9=H.|date=2012-11|title=RET fusion genes are associated with chronic myelomonocytic leukemia and enhance monocytic differentiation|url=https://pubmed.ncbi.nlm.nih.gov/22513837|journal=Leukemia|volume=26|issue=11|pages=2384–2389|doi=10.1038/leu.2012.109|issn=1476-5551|pmid=22513837}}</ref> | ||
| | |Rare <5% | ||
| | |D, P, T | ||
| | |Yes (WHO) | ||
| | |Associated with chronic myelomonocytic leukemia and monocytic differentiation. The prognosis remains unclear due to the limited number of cases. | ||
|} | |} | ||
==Individual Region Genomic Gain/Loss/LOH== | ==Individual Region Genomic Gain/Loss/LOH== | ||